<p>(Mean± SEM): a) oral glucose tolerance test done at 16 weeks (n = 9 control, n = 8 DHT+liraglutide and n = 10 DHT). b): Area under the curve during OGTT for different groups. c): Total cholesterol measured at the end of the study (88–90 days from pellet/sham implantation) after 10 hour fast (n = 8 rats in DHT and DHT+ liraglutide group and n = 5 in control group). * denotes p<0.05 between DHT and DHT+ liraglutide and DHT and control.</p
The incretin effect is essential for glucose homeostasis. Glucagon-like peptide 1 (GLP-1) based drug...
IntroductionThe incretin hormone glucagon-like peptide-1 (GLP-1) slows gastric emptying, increases s...
Background: Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glyc...
<p>(Mean± SEM; g): a) Rats were weighed at 4 weeks and again from 9–13 weeks and at 16 week. “#” den...
<p>(A) body weights during liraglutide treatment (n = 6–7). Open circles, liraglutide-treated <i>Gcg...
<p>(Mean± SEM; mmHg)<b>:</b> a) Day time radiotelemeter data starting at 14 weeks of age: Data is av...
<p>The body weight (A) and random fed state blood glucose levels (B) were monitored weekly in vehicl...
<p>Blood glucose and serum insulin levels during 1.5 g/kg OGTT on day 15 (<b>a</b>) and day 30 (<b>b...
<p><b>DHT levels and estrous cycle pattern:</b> a) <b>DHT levels measured at 16 weeks of age.</b> (M...
<p>[A] Line curves depict the changes in blood glucose response in normal control, diabetic control,...
<p>(A) OGTT in diabetic ZDF rat (▪, black squares), normal ZLC rats (□, white squares), rosiglitazon...
<p>(A) Body weight change (% of day 0), (B) Cumulative total energy intake (kJ), (C) cumulative inta...
ObjectiveThe efficacy of liraglutide, a human glucagon-like peptide-1 (GLP-1) analog, to prevent or ...
(A) An OGTT was performed before the 6 weeks of administration, and area under the curve (AUC) is sh...
<p>(<b>a</b>) Schematic representation of the study. (<b>b</b>) Body weight. There is no difference ...
The incretin effect is essential for glucose homeostasis. Glucagon-like peptide 1 (GLP-1) based drug...
IntroductionThe incretin hormone glucagon-like peptide-1 (GLP-1) slows gastric emptying, increases s...
Background: Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glyc...
<p>(Mean± SEM; g): a) Rats were weighed at 4 weeks and again from 9–13 weeks and at 16 week. “#” den...
<p>(A) body weights during liraglutide treatment (n = 6–7). Open circles, liraglutide-treated <i>Gcg...
<p>(Mean± SEM; mmHg)<b>:</b> a) Day time radiotelemeter data starting at 14 weeks of age: Data is av...
<p>The body weight (A) and random fed state blood glucose levels (B) were monitored weekly in vehicl...
<p>Blood glucose and serum insulin levels during 1.5 g/kg OGTT on day 15 (<b>a</b>) and day 30 (<b>b...
<p><b>DHT levels and estrous cycle pattern:</b> a) <b>DHT levels measured at 16 weeks of age.</b> (M...
<p>[A] Line curves depict the changes in blood glucose response in normal control, diabetic control,...
<p>(A) OGTT in diabetic ZDF rat (▪, black squares), normal ZLC rats (□, white squares), rosiglitazon...
<p>(A) Body weight change (% of day 0), (B) Cumulative total energy intake (kJ), (C) cumulative inta...
ObjectiveThe efficacy of liraglutide, a human glucagon-like peptide-1 (GLP-1) analog, to prevent or ...
(A) An OGTT was performed before the 6 weeks of administration, and area under the curve (AUC) is sh...
<p>(<b>a</b>) Schematic representation of the study. (<b>b</b>) Body weight. There is no difference ...
The incretin effect is essential for glucose homeostasis. Glucagon-like peptide 1 (GLP-1) based drug...
IntroductionThe incretin hormone glucagon-like peptide-1 (GLP-1) slows gastric emptying, increases s...
Background: Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glyc...